Tag: NASDAQ:ESPR

Finance

Investors Alert : The Charles Schwab (NYSE:SCHW), Comcast (NASDAQ:CMCSA), Esperion Therapeutics, Inc. (NASDAQ:ESPR), Platinum Underwriters Holdings (NYSE:PTP), AT&T, Inc. (NYSE:T),

Charles Schwab Corp (NASDAQ:SCHW) EVP James D. Mccool sold 35,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $30.10, for a total value of $1,053,500.00. Following the transaction, the executive vice president now directly owns 84,905 shares of the company’s stock, valued at approximately $2,555,641. The … Continue reading Investors Alert : The Charles Schwab (NYSE:SCHW), Comcast (NASDAQ:CMCSA), Esperion Therapeutics, Inc. (NASDAQ:ESPR), Platinum Underwriters Holdings (NYSE:PTP), AT&T, Inc. (NYSE:T),

Kristen Barton
Finance

Active Watch List : Esperion Therapeutics (NASDAQ:ESPR), Office Depot (NYSE:ODP), Universal Forest NASDAQ:UFPI), First Financial Bankshares (NASDAQ:FFIN), Eldorado (NYSE:EGO)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, on 12 Aug 2014 provided ETC-1002 development program updates and financial results for the second quarter ended June 30, 2014. In July, company initiated enrollment in the Phase 2 ETC-1002-014 study in 144 patients … Continue reading Active Watch List : Esperion Therapeutics (NASDAQ:ESPR), Office Depot (NYSE:ODP), Universal Forest NASDAQ:UFPI), First Financial Bankshares (NASDAQ:FFIN), Eldorado (NYSE:EGO)

Jason Knox
Finance

Losers to Watch: Esperion Therapeutics Inc (NASDAQ:ESPR), Egalet Corp (NASDAQ:EGLT), Ocera Therapeutics (NASDAQ:OCRX), La Jolla Pharmaceutical (NASDAQ:LJPC), Omeros (NASDAQ:OMER)

In June, Esperion Therapeutics Inc. (NASDAQ:ESPR), an Ann Arbor-based early-stage pharmaceutical company, raised $73 million in its IPO. It plans a secondary offering this year, based on trial results of its cholesterol-lowering drug. Esperion Therapeutics Inc (NASDAQ:ESPR) stock performance was -5.04% in last session and finished the day at $14.69. Traded volume was 31,400 shares in the last session and the average volume of the … Continue reading Losers to Watch: Esperion Therapeutics Inc (NASDAQ:ESPR), Egalet Corp (NASDAQ:EGLT), Ocera Therapeutics (NASDAQ:OCRX), La Jolla Pharmaceutical (NASDAQ:LJPC), Omeros (NASDAQ:OMER)

John Bellich
Finance

Today’s Watch List: Coca-Cola Company (NYSE:KO), Williams Companies (NYSE:WMB), Universal Electronics Inc. (NASDAQ:UEIC), Horace Mann Educators (NYSE:HMN), Esperion (NASDAQ:ESPR)

On 5 AUG The Coca-Cola Company (NYSE:KO) said that The Coca-Cola Company (NYSE:KO) and its African bottling partners today announced a new investment of US$5 billion during the U.S.-Africa Leaders Summit here. The investment, to be made over the next six years, increases its total announced investment in Africa to $17 billion from 2010 to 2020.The Coca-Cola Company (NYSE:KO) belongs to Consumer Goods sector. Its … Continue reading Today’s Watch List: Coca-Cola Company (NYSE:KO), Williams Companies (NYSE:WMB), Universal Electronics Inc. (NASDAQ:UEIC), Horace Mann Educators (NYSE:HMN), Esperion (NASDAQ:ESPR)

Mark DeFrance
Finance

Hot Biotech Bullish Stocks: Genocea Biosciences (NASDAQ:GNCA), Esperion Therapeutics (NASDAQ:ESPR), Anacor Pharmaceuticals (NASDAQ:ANAC), CEL-SCI (NYSEMKT:CVM)

Vaccine specialist Genocea Biosciences Inc (NASDAQ:GNCA) struck a research deal with Dana-Farber Cancer Institute and Harvard Medical School to study cancer immunology. Under the March 5 alliance, researchers will use Genocea Biosciences Inc (NASDAQ:GNCA)’s proprietary T cell antigen discovery platform to find antigens that correlate with an anti-tumor immune response in melanoma patients. Genocea Biosciences Inc (NASDAQ:GNCA) stock performance was 23.28% in last session and … Continue reading Hot Biotech Bullish Stocks: Genocea Biosciences (NASDAQ:GNCA), Esperion Therapeutics (NASDAQ:ESPR), Anacor Pharmaceuticals (NASDAQ:ANAC), CEL-SCI (NYSEMKT:CVM)

Jayne Crisman